49 completed, 17 recruiting, 14 terminated, 10 unknown. 30 Not applicable, 24 Phase 2, 19 Phase 1, 7 Phase 3.
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS [11C]CPPC PET ligand - ALS | Phase 1 / Phase 2 | Not yet recruiting | Johns Hopkins University | 20 | 2026-11-01 | 2026-08-25 |
| The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab Foralumab Nasal, Placebo - ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis | Phase 2 | Not yet recruiting | Tiziana Life Sciences LTD | 44 | 2026-09-25 | 2026-10-21 |
| Digital Speech Markers for Monitoring ALS in Spanish Speakers Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease | Not yet recruiting | Nova Southeastern University | 35 | 2026-08-01 | 2026-08-03 | |
| Healey ALS MyMatch Common Screening Protocol ALS, ALS (Amyotrophic Lateral Sclerosis) | Not yet recruiting | Massachusetts General Hospital | 500 | 2026-08-01 | 2026-07-29 | |
| Multimodal Tracking of Therapy Activity and Effort During Rehabilitation Stroke, Cerebral Palsy | Active not recruiting | ETH Zurich | 10 | 2026-06-01 | 2026-07-31 | |
| INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study Stentrode - Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis) | Not applicable | Recruiting | Synchron, Inc. | 10 | 2026-05-07 | 2026-10-21 |
| A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients PLL001 or placebo daily subcutaneous injections - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Not yet recruiting | PLL TX AUSTRALIA PTY LTD | 153 | 2026-04-08 | 2026-03-19 |
| Functional Outcomes and Control Using Synchron BCI - Canada Stentrode - Neurologic Disorder, ALS | Not applicable | Recruiting | Synchron, Inc. | 10 | 2026-03-18 | 2026-04-17 |
| Chinese-Specific Speech Imagery Coding Using High-Density ECoG Intraoperative high-density ECoG recording, Permanent high-density ECoG implantation - Aphasia, Dysarthria | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2026-03-15 | 2026-03-10 |
| Kamlanoflast In Amyotrophic Lateral Sclerosis Kamlanoflast - ALS (Amyotrophic Lateral Sclerosis), ALS | Phase 1 / Phase 2 | Not yet recruiting | Inflammasome Therapeutics | 40 | 2026-02-01 | 2026-02-09 |
| Systems Biology of Amyotrophic Lateral Sclerosis (ALS) ALS, ALS (Amyotrophic Lateral Sclerosis) | Not yet recruiting | Viome | 20 | 2025-06-01 | 2025-06-05 | |
| At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis Real tDCS, Sham tDCS - ALS, ALS (Amyotrophic Lateral Sclerosis) | Not applicable | Recruiting | University of Trieste | 40 | 2025-05-19 | 2025-06-13 |
| Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) Next Generation Dome Helmet Focused Ultrasound, Intravenous immunoglobulin (IVIG), 10% solution for infusion, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Active not recruiting | Sunnybrook Health Sciences Centre | 6 | 2025-04-15 | 2026-07-14 |
| AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis AMX0114, Placebo - ALS | Phase 1 | Recruiting | Amylyx Pharmaceuticals Inc. | 48 | 2025-04-07 | 2026-04-14 |
| RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq) - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Macquarie University, Australia | 12 | 2024-11-15 | 2025-06-08 |
| Multicenter ALS Imaging Study Magnetic Resonance Imaging, Plasma neurofilament light chain (NfL) quantification - Amyotrophic Lateral Sclerosis, ALS | Recruiting | University of Minnesota | 90 | 2024-09-15 | 2026-07-31 | |
| Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01) BrainGate Neural Interface System - Brainstem Stroke, ALS | Not applicable | Recruiting | Leigh R. Hochberg, MD, PhD. | 6 | 2024-07-22 | 2026-10-26 |
| Clinical Trial - Analyzing Participation Experiences Of Amyotrophic Lateral Sclerosis Patients ALS, Amyotrophic Lateral Sclerosis | Unknown | Power Life Sciences Inc. | 500 | 2024-07-01 | 2024-01-02 | |
| Using the EHR to Advance Genomic Medicine Across a Diverse Health System Behavioral nudge - Genetic Predisposition, Paraganglioma | Not applicable | Recruiting | University of Pennsylvania | 1000 | 2024-06-10 | 2026-08-14 |
| A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients TCD601 - ALS | Phase 1 | Terminated | ITB-Med LLC | 7 | 2024-04-16 | 2026-07-17 |
Showing 20 of 108. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (52) · Motor Neuron Disease (19) · Parkinson Disease (7) · Alzheimer Disease (6) · Neurodegenerative Diseases (6) · Multiple Sclerosis (5) · Nervous System Diseases (5) · Spinal Cord Injuries (5) · Stroke (5) · Neoplasms (4) · Cognitive Dysfunction (3) · Dementia (3) · Frontotemporal Dementia (3) · Huntington Disease (3) · Macular Degeneration (3)
Central Nervous System Diseases (63) · Nervous System Diseases (63) · Neuromuscular Diseases (57) · Spinal Cord Diseases (56) · Metabolic Diseases (55) · Neurodegenerative Diseases (55) · Nutritional and Metabolic Diseases (55) · Proteostasis Deficiencies (54) · TDP-43 Proteinopathies (53) · Motor Neuron Disease (36) · Pathological Conditions, Signs and Symptoms (18) · Brain Diseases (13) · Pathologic Processes (12) · Signs and Symptoms (11) · Mental Disorders (10)
Edaravone (5) · Probiotics (2) · Riluzole (2) · Sodium Chloride (2) · Spinal Puncture (2) · sodium phenylbutyrate and taurursodiol (2) · (11C)-MC1 (1) · (methyl-(11)C)N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine (1) · 11C-PS13 (1) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · 4-phenylbutyric acid (1) · Acetates (1) · Ashwagandha (1) · Biotin (1) · Blood Specimen Collection (1)
Shionogi (5) · Massachusetts General Hospital (4) · Amylyx Pharmaceuticals Inc. (3) · Barrow Neurological Institute (3) · Duke University (3) · Milton S. Hershey Medical Center (3) · Biohaven Pharmaceuticals, Inc. (2) · Columbia University (2) · Hospital for Special Surgery, New York (2) · Mayo Clinic (2) · National Institute of Environmental Health Sciences (NIEHS) (2) · NeuroSense Therapeutics Ltd. (2) · New York Stem Cell Foundation Research Institute (2) · Nova Southeastern University (2) · Sunnybrook Health Sciences Centre (2)
United States (66) · Canada (17) · France (12) · Italy (11) · Israel (6) · Japan (6) · Germany (5) · South Korea (4) · Switzerland (4) · Australia (3) · Belgium (3) · Netherlands (3) · Spain (3) · Sweden (3) · United Kingdom (3)
Matthew Harms, MD (2) · Shafeeq Ladha, MD (2) · Agessandro Abrahao, MD, MSc (1) · Alberto Benussi, MD (1) · Alexander Sherman (1) · Anthony J Windebank, MD (1) · Athena F Zuppa, MD MSCE (1) · Barbara Smith (1) · Bjorn E Oskarsson, MD (1) · Chafic Karam, MD (1) · Christel Saint-Raymond, PhD (1) · Corey McMillan, PhD (1)
PMID 15512895, PMID 18421218, PMID 18421219, PMID 19153849, PMID 19922120, PMID 21652288, PMID 22531737, PMID 22692932, PMID 23613806, PMID 24284925, PMID 25297012, PMID 25934946, PMID 28864675, PMID 29160240, PMID 30048006, PMID 31523813, PMID 32140672, PMID 32646955, PMID 33063909, PMID 34075589, PMID 34260835, PMID 34426551, PMID 34476128, PMID 34981890, PMID 35508892, PMID 35577511, PMID 36347863, PMID 36504406, PMID 37695623, PMID 38606777, PMID 39160614, PMID 39192497, PMID 39542698, PMID 39710171, PMID 40343020, PMID 40353311, PMID 40474686, PMID 40720979, PMID 41202295, PMID 41837970, PMID 42083927
2019 (2), 1RC1EB010915-01 (1), R21NS118434 (1), U01DC017844 (1), U01DC018671 (1), U01NS049640 (1), U01NS136022 (1), U01NS136023 (1)